[{"orgOrder":0,"company":"Bionaut Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bionaut Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bionaut Labs \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bionaut Labs \/ Inapplicable"}]

Find Oncology Clinical Drug Pipeline Developments & Deals by Bionaut Labs

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Vietnam Medi-Pharm Expo
                          Not Confirmed
                          Vietnam Medi-Pharm Expo
                          Not Confirmed

                          Details : BNL-101 is a drug-device combination comprised of doxorubicin as the active drug component together with the company's Bionaut™ microscale robots.

                          Product Name : BNL-101

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          June 23, 2021

                          Lead Product(s) : Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank